ViroGates A/S (VIRO) Earnings Call Transcripts
ViroGates A/S's Latest Earnings Call - March 27, 2026
In the fiscal year 2025, ViroGates A/S reported revenue of DKK 5.3 million, reflecting an 8% increase year-over-year, driven by growing interest in preventative health and longevity products. The company's net loss improved by 28% to DKK 10.4 million, aided by increased revenue and a reduction in operating expenses. Management highlighted significant milestones, including FDA feedback on their suPARnostic TurbiLatex product and a successful capital raise of DKK 19.3 million, indicating a strengthened financial position and commitment to growth in the longevity market.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | DKK 5.3 million (beat) |
| Net Loss | DKK 10.4 million (positive) |
| Other Income | DKK 3.6 million (positive) |
| Operating Expenses | DKK 10.4 million (positive) |
| Operating Cash Burn | DKK 4.1 million (positive) |
| Cash Position | DKK 26.3 million (positive) |
Guidance from management
Management indicated that they expect to file the de novo application for the suPARnostic TurbiLatex product with the FDA in the first half of 2026, signaling a focus on regulatory compliance and product development.
What analysts pressed on
Analysts expressed concerns regarding the speed of product development, particularly for the POC+ product. There were questions about the timeline for clinical verification and the potential impact on sales growth.
Main topics on the call
- Revenue Growth — ViroGates achieved an 8% revenue growth to DKK 5.3 million, attributed to increased traction in the preventative health and longevity segment. Management stated, "we are experiencing that more customers are interested in...
- Improved Net Loss — The company reported a net loss of DKK 10.4 million, a 28% improvement from DKK 14.3 million in 2024. This reduction reflects both revenue growth and a decrease in operating expenses, as noted by management, "an overall ...
- FDA Pathway Clarity — Management confirmed that the suPARnostic TurbiLatex requires a de novo pathway for FDA approval, providing regulatory clarity moving forward. CEO Jakob Knudsen mentioned, "we expect to do this during the first half of t...
- Capital Raise Success — ViroGates successfully raised DKK 19.3 million through a directed capital raise, enhancing their financial position. This was highlighted as a significant step, with management stating, "the investment entity behind suPA...
Read the full ViroGates A/S transcript (March 27, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About ViroGates A/S
ViroGates A/S (VIRO) is a publicly listed company in the Health Care Equipment and Supplies industry, within the Health Care sector. It trades on CPSE and is based in DK. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 4 calls on record spanning March 21, 2025 to August 21, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 4 ViroGates A/S earnings call transcripts on record, spanning March 21, 2025 to August 21, 2026. Based on this history, ViroGates A/S reports semi-annually. The most recent call on file is dated August 21, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- VIRO
- Exchange
- CPSE
- Country
- DK
- Sector
- Health Care
- Calls on record
- 4
- First call
- March 21, 2025
- Most recent
- August 21, 2026
- Reporting cadence
- semi-annually
| Quarter | Date | |
|---|---|---|
| Earnings Calls | Aug 21, 2026 | Read transcript → |
| Earnings Calls | Mar 27, 2026 | Read transcript → |
| Q3 FY2025 | Nov 10, 2025 | Read transcript → |
| Earnings Calls | Mar 21, 2025 | Read transcript → |